肿瘤过继细胞治疗（adoptive cell therapy，ACT）较早被提出并一度盛行，但长期以来其疗效不佳，逐渐淡出人们视野。近年来，肿瘤ACT取得长足进步，利用T细胞过继免疫治疗黑素瘤获得令人鼓舞的成功；利用细胞因子诱导的杀伤细胞（cytokine induced killer cell, CIK）治疗癌症也在我国兴起，并取得可喜成绩。在肿瘤ACT领域，仍面临选择什么样的效应细胞、如何高效诱导筛选T细胞克隆、是否采用T细胞TCR转基因技术、如何通过武装化T细胞提高疗效、如何评判肿瘤ACT疗效等方面的问题。

Adoptive cell therapy (ACT) of cancer has long been proposed, but was gradually forgotten due to its disappointing efficacy. In recent years, great improvement has been made in cancer ACT．ACT with adoptive T cells for immunotherapy of melanoma has achieved impressive outcomes. And CIK（cytokine induced killer cells）has been widely used in clinical treatment of cancers in China, and satisfactory results have been obtained. However, several problems remain to be solved: what kind of cells are suitable for adoptive transfer? How to efficiently induce and screen T cell clones? Whether and how to rapidly amplify T cells through TCR transgenic strategy? How to genetically engineer T cells to improve the efficacy of ACT, and how to properly evaluate the efficacy of ACT, etc.

国家杰出青年科学基金资助（No.30925037）；艾滋病和病毒性肝炎等重大传染病的防治科技重大专项基金资助项目（No. 2008ZX10002-023）。